Table 1.
Aflibercept for neovascular age-related macular degeneration 3-year outcomes. Data regarding visual acuity, OCT macular thickness, macular morphology and number of injections for patients completing 1, 2 and 3 years of follow-up
| Analysis of the cohort | ||||
|---|---|---|---|---|
| Baseline | Year 1 | Year 2 | Year 3 | |
| 148 eyes | 148 eyes | 131 eyes | 108 eyes | |
| Eyes which lost 15 letters or more (%) | N/A | 6.8% | 9.2% | 11.1% |
| Eyes which improved by 15 letters or more (%) | N/A | 25% | 28.2% | 30.5% |
| Eyes with VA ≥ 20/40, 73 ETDRS letters (%) | 10.8% | 30.4% | 38.9% | 28.7% |
| Baseline mean BCVA (ETDRS letters) | 54.4 ± 16 | 60.3 ± 18.1 | 60.8 ± 17.4 | 61 ± 16.6 |
| Mean gain in VA (ETDRS letters) | N/A | 5.9 ± 13.8 | 6.4 ± 14.9 | 6.6 ± 15.4 |
| Change in OCT (microns) | N/A | − 71.2 ± 99.7 | − 74.7 ± 94.5 | − 77.9 ± 101.4 |
| % of eyes with no macular fluid | N/A | 66.7% | 61.3% | 66.7% |
| Number of injections | N/A | 7.2 ± 1.8 | 12 ± 3.8 | 15.9 ± 6.1 |